Tingting Yi

Randomized, double-blind study of sonidegib (LDE225) in patients (pts) with locally advanced (La) or metastatic (m) basal-cell carcinoma (BCC)

R. Dummer, L. Dirix, R. Gutzmer, 2014 .

Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study

R. Dummer, R. Plummer, L. Dirix, 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.

Debra F. Weinstein, Michael G. Miller, M. A. Ferreira, 2019, Lancet.

Series test of cluster and network analysis for lupus nephritis, before and after IFN‐K‐immunosuppressive therapy

T. Yi, Ping Li, Sen Luan, 2018, Nephrology.

Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial.

R. Dummer, R. Plummer, L. Dirix, 2015, The Lancet. Oncology.

The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma.

R. Dummer, R. Plummer, L. Dirix, 2016, Journal of the American Academy of Dermatology.

Treatment with two diff erent doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma ( BOLT ) : a multicentre , randomised , double-blind phase 2 trial

R. Dummer, R. Plummer, L. Dirix, 2015 .

LncRNA LINC00680 Acts as a Competing Endogenous RNA and Is Associated With the Severity of Myasthennia Gravis

Lihua Wang, T. Yi, Lei Li, 2022, Frontiers in Neurology.